Monopar Therapeutics Cash And Cash Equivalents At Carrying Value

Quick Answer

Monopar Therapeutics reported Cash And Cash Equivalents At Carrying Value of $61.83 million for the year ending 2025.

  • Monopar Therapeutics showed an increase of +35.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from Monopar Therapeutics's annual report (Form 10-K), filed with the SEC on March 27, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2016 to 2025), Monopar Therapeutics's Cash And Cash Equivalents At Carrying Value has grown by 2,883.4%.
  • Historical annual values: Fiscal year 2025: $61.83 million | Fiscal year 2024: $45.82 million | Fiscal year 2023: $7.27 million | Fiscal year 2022: $8.19 million | Fiscal year 2021: $20.30 million | Fiscal year 2020: $16.74 million | Fiscal year 2019: $13.21 million | Fiscal year 2018: $6.89 million | Fiscal year 2017: $8.98 million | Fiscal year 2016: $2.07 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: